

Ву

Patent Application Attorney Docket No.PC10759A RESPONSE AFTER FINAL OFFICIAL ACTION **EXPEDITED PROCEDURE REQUESTED** 

hereby certify that this correspondence is being deposited with the United/States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, y/1/22313-1450 on this day of April 2004.

ere of person mailing) Andrea E. Dorigo Reg. No. 47,532 (Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Chen, Yuhpyng L.

Examiner: Truong, T. N.

**APPLICATION NO.: 09/761,995** 

Group Art Unit: 1624

FILING DATE: 01/17/2001

TITLE: CORTICOTROPIN RELEASING

**FACTOR ANTAGONISTS** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **BOX AF** 

RESPONSE TO FINAL OFFICIAL ACTION UNDER 37 CFR 1.116

Sir:

This is in response to the Final Official Action for the above-captioned application mailed April 1, 2004. Please amend this application as follows:

USERS\DOCS\LA21952\LPAEDMFTY011.DOC/207142

1202 12×18-216

-1-

06/18/2004 FMERCER 00000001 161445

Patent Application
Attorney Docket No.PC10759A
RESPONSE AFTER FINAL OFFICIAL ACTION
EXPEDITED PROCEDURE REQUESTED

created doctrine of obviousness double patenting. Withdrawal of the rejection is respectfully requested.

Claims 1, 3, 5-11 and 17 have been rejected under 35 USC 102 as allegedly anticipated by Chen (WO 95/33750). According to the Examiner, the cited reference is anticipatory for A = CH,  $R_3$  = CH<sub>3</sub>, B = NR<sub>1</sub>R<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> are independently C<sub>2</sub>-C<sub>3</sub> alkyl; R<sub>4</sub> = CONR<sub>24</sub>R<sub>25</sub> or COOR<sub>24</sub>; Z = O; R<sub>5</sub> = phenyl.

However, it is respectfully submitted that Claims 1, 3, 5-11 and 17 are not anticipated by Chen. Claim 1 has been amended for the sake of expediting prosecution to delete the recitation  ${}^{\alpha}C_1$ - ${}^{\alpha}C_6$  alkyl from the definition of  ${}^{\alpha}C_1$ . Claims 6 and 7 have been similarly amended. Chen does not disclose  ${}^{\alpha}C_1$  as defined in Claims 1, 6 and 7 as amended. With regard to Claim 8, purely for the sake of expediting prosecution, the compound recited in the last line of Claim 8 of the instant application has been cancelled. Claim 8 has also been rewritten in independent form.

In view of the foregoing, Chen does not anticipate Claims 1, 3, 5-11 and 17. Withdrawal of the rejection under 35 USC 102 of Claims 1, 3, 5-11 and 17 as allegedly anticipated by Chen is respectfully requested.

New Claims 23-27, 28-32, 33, and 34 have been added to recite the limitations cancelled from, respectively, Claims 9, 10, 14 and 20 identified above. It is respectfully submitted that new Claims 23-34 do not introduce new matter. It is respectfully submitted that the new claims, which depend on patentable claims, are themselves patentable. Applicants further point out that new Claims 25 and 26, dependent on Claim 9, and new Claims 30 and 31, dependent on Claim 10, are directed to depression and forms of depression, which are supported by an enabling disclosure, by Examiner's own acknowledgment (see Official Action, page 4, para. 2, first sentence). Accordingly, new Claims 25, 26, 30 and 31 are patentable for this additional reason.

In view of the foregoing, reconsideration of all rejections and allowance of all pending claims is respectfully requested.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: April , 2004

Andrea Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc Patent Department 150 East 42nd Street – 5<sup>th</sup> Floor New York, NY 10017-5755 (212) 733-3381